Risk for Zoster Up Before Dx, During Tx of Hematologic Cancer
For solid organ cancers, the risk is greater among those receiving chemotherapy
MONDAY, Dec. 17, 2018 (Pharmacist's Briefing) -- The risk for herpes zoster (zoster) is elevated during the two years preceding diagnosis and during treatment of hematological cancer, according to a study published online Dec. 13 in the Journal of Infectious Diseases.
Jiahui Qian, M.P.H., from the University of New South Wales in Sydney, and colleagues conducted a prospective cohort study involving 241,497 adults (mean age, 62.0 years at recruitment in 2006 to 2009) linked to health datasets (2006 to 2015). Using time-varying proportional hazard models, the authors analyzed the relation between cancer diagnosis, treatment, and zoster risk.
There were 20,286 new cancer diagnoses and 16,350 zoster events during 1,760,481 person-years of follow-up. The researchers found that compared with those without cancer, participants with hematological and solid cancers had higher relative risks for zoster (adjusted hazard ratios, 3.47 and 1.30, respectively). Zoster risk was also elevated prior to a hematological cancer diagnosis compared with those without cancer; however, this was not the case for solid cancers. Compared with those without cancer, the risk for zoster was higher for participants with solid cancers receiving chemotherapy than for those not receiving chemotherapy (adjusted hazard ratios, 1.83 and 1.16, respectively).
"Zoster vaccination now holds promise as a preventive strategy considered for cancer patients, particularly those expected to receive chemotherapy," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.